本帖最后由 老马 于 2013-3-13 13:43 编辑
6 f B; d& c2 v
+ a/ k( ~* E! A/ _7 O2 k" w. U健择(吉西他滨)+顺铂+阿瓦斯汀! \3 B, A9 F5 q5 K: h+ J
Gemzar +Cisplatin + Avastin5 f _ r( N$ Q8 P7 q
http://annonc.oxfordjournals.org/content/21/9/1804.full
2 x- X% ?2 R, ~- g0 X# ~Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) % i& x1 `' G$ Y* W
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 2 E; k5 A" D+ _; j2 y3 a# `3 T
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ) ]( Y |5 _8 i6 u0 y. {9 `$ e- P8 g: l
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 759)
: \4 m9 \5 E5 G7 p E: @
华为网盘附件:
! y" B( [! C, C: O0 r$ d【华为网盘】ava.JPG
/ j8 k" A; U& R" c0 L |